[{"id":"ad1d963e-b163-427e-be70-2d37437a6605","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471841","created_at":"2026-03-28T01:44:38.203Z","updated_at":"2026-03-28T01:44:38.203Z","phase":"Phase 2","brief_title":"Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax","source_id_and_acronym":"NCT07471841","lead_sponsor":"Timothy Pardee","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Rezlidhia (olutasidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 05/01/2026","start_date":" 05/01/2026","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2026-03-13"},{"id":"5dbd5ae2-c64a-4324-a92e-acf2900c0634","acronym":"CHANCE","url":"https://clinicaltrials.gov/study/NCT07172204","created_at":"2025-09-20T07:07:45.699Z","updated_at":"2025-09-20T07:07:45.699Z","phase":"Phase 2","brief_title":"Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML","source_id_and_acronym":"NCT07172204 - CHANCE","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 08/15/2025","start_date":" 08/15/2025","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 07/31/2029","study_completion_date":" 07/31/2029","last_update_posted":"2025-09-15"},{"id":"17c029cc-5449-4ba9-99f6-13ebaefd3227","acronym":"EVOLVE 1","url":"https://clinicaltrials.gov/study/NCT07075016","created_at":"2025-07-26T13:34:40.222Z","updated_at":"2025-07-26T13:34:40.222Z","phase":"Phase 3","brief_title":"Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy","source_id_and_acronym":"NCT07075016 - EVOLVE 1","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 227","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-07-20"},{"id":"1d2cc1b3-1db7-4ec6-826d-f95392ccf5c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT07012447","created_at":"2025-06-14T13:57:18.760Z","updated_at":"2025-06-14T13:57:18.760Z","phase":"Phase 2","brief_title":"Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations","source_id_and_acronym":"NCT07012447","lead_sponsor":"yuejun Liu","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-06-10"},{"id":"7cd7c85e-4e1b-46fd-8491-96d1bcc8b391","acronym":"IMGN632-0802","url":"https://clinicaltrials.gov/study/NCT04086264","created_at":"2021-01-18T20:00:09.580Z","updated_at":"2025-02-25T12:27:19.012Z","phase":"Phase 1/2","brief_title":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia","source_id_and_acronym":"NCT04086264 - IMGN632-0802","lead_sponsor":"AbbVie","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • pivekimab sunirine (PVEK)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 218","initiation":"Initiation: 11/06/2019","start_date":" 11/06/2019","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-24"},{"id":"9e19f934-321f-4e6c-b066-71f0217f0bae","acronym":"","url":"https://clinicaltrials.gov/study/NCT03041688","created_at":"2021-01-18T14:58:33.453Z","updated_at":"2025-02-25T12:26:38.524Z","phase":"Phase 1","brief_title":"Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT03041688","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • CD4","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • TP53 wild-type","tags":["TP53 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • navtemadlin (KRT-232)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 02/08/2018","start_date":" 02/08/2018","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-24"},{"id":"23ac8e6c-a9b5-4a23-995c-206f44787ba3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02890329","created_at":"2021-01-18T14:11:09.765Z","updated_at":"2025-02-25T13:48:17.623Z","phase":"Phase 1","brief_title":"Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia","source_id_and_acronym":"NCT02890329","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" High ALC","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e High ALC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • azacitidine • decitabine • CS1002 (ipilimumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/05/2017","start_date":" 09/05/2017","primary_txt":" Primary completion: 10/24/2022","primary_completion_date":" 10/24/2022","study_txt":" Completion: 08/19/2025","study_completion_date":" 08/19/2025","last_update_posted":"2025-02-21"},{"id":"a2748e44-3f76-4ef4-9c24-1b7476039a69","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554393","created_at":"2022-09-26T14:56:10.693Z","updated_at":"2025-02-25T13:49:33.606Z","phase":"Phase 2","brief_title":"Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)","source_id_and_acronym":"NCT05554393","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation","tags":["TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 09/13/2024","start_date":" 09/13/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-20"},{"id":"f5056d6b-3ffd-4e44-961f-b461e0552213","acronym":"A051902","url":"https://clinicaltrials.gov/study/NCT04803201","created_at":"2021-03-17T15:57:46.362Z","updated_at":"2025-02-25T14:15:53.168Z","phase":"Phase 2","brief_title":"Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT04803201 - A051902","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" TNFRSF8 expression","tags":["PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • azacitidine • cyclophosphamide • etoposide IV • Copiktra (duvelisib) • vincristine • prednisone • Onureg (azacitidine oral) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 10/08/2021","start_date":" 10/08/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-18"},{"id":"ae37ad26-112d-406e-b4ec-b9bd80c911c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05292664","created_at":"2022-03-23T13:53:35.750Z","updated_at":"2025-02-25T14:08:44.222Z","phase":"Phase 1","brief_title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","source_id_and_acronym":"NCT05292664","lead_sponsor":"Andrew E. Place, MD","biomarkers":" FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1","pipe":" | ","alterations":" KMT2A rearrangement • ABL1 fusion","tags":["FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • azacitidine • vincristine • leucovorin calcium • Asparlas (calaspargase pegol-mknl) • dexrazoxane"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 03/29/2023","start_date":" 03/29/2023","primary_txt":" Primary completion: 07/02/2026","primary_completion_date":" 07/02/2026","study_txt":" Completion: 07/02/2028","study_completion_date":" 07/02/2028","last_update_posted":"2025-02-17"},{"id":"2770c644-c8c6-4b54-8f58-0b1d8f8f4795","acronym":"IO-202-CL-001","url":"https://clinicaltrials.gov/study/NCT04372433","created_at":"2023-05-17T22:04:43.287Z","updated_at":"2025-02-25T14:40:35.488Z","phase":"Phase 1","brief_title":"IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML","source_id_and_acronym":"NCT04372433 - IO-202-CL-001","lead_sponsor":"Immune-Onc Therapeutics","biomarkers":" LILRB4","pipe":"","alterations":" ","tags":["LILRB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • IO-202"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2025-02-14"},{"id":"d1bc1259-71d0-45e4-a4ce-99f4232d61c4","acronym":"AZURE","url":"https://clinicaltrials.gov/study/NCT05609942","created_at":"2023-04-03T15:02:58.943Z","updated_at":"2025-02-25T14:41:39.851Z","phase":"Phase 1","brief_title":"Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies","source_id_and_acronym":"NCT05609942 - AZURE","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA D842V • PDGFRA mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA D842V • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • elenestinib (BLU-263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 01/14/2025","primary_completion_date":" 01/14/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-14"},{"id":"c84b4894-7b72-40e5-b7d9-73619eecd885","acronym":"22P.205","url":"https://clinicaltrials.gov/study/NCT05564650","created_at":"2022-10-03T15:56:48.447Z","updated_at":"2025-02-25T15:35:52.261Z","phase":"Phase 1/2","brief_title":"Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT05564650 - 22P.205","lead_sponsor":"Thomas Jefferson University","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • navitoclax (ABT 263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 01/12/2023","start_date":" 01/12/2023","primary_txt":" Primary completion: 04/10/2026","primary_completion_date":" 04/10/2026","study_txt":" Completion: 04/10/2026","study_completion_date":" 04/10/2026","last_update_posted":"2025-02-11"},{"id":"f1031737-80a9-4c8b-a2a6-14dc6ec95216","acronym":"SL03-OHD-104","url":"https://clinicaltrials.gov/study/NCT05275439","created_at":"2022-03-11T15:53:40.765Z","updated_at":"2025-02-25T15:44:45.150Z","phase":"Phase 1","brief_title":"Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML","source_id_and_acronym":"NCT05275439 - SL03-OHD-104","lead_sponsor":"Shattuck Labs, Inc.","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • SL-172154"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 03/17/2022","start_date":" 03/17/2022","primary_txt":" Primary completion: 02/06/2025","primary_completion_date":" 02/06/2025","study_txt":" Completion: 02/06/2025","study_completion_date":" 02/06/2025","last_update_posted":"2025-02-11"},{"id":"35a86a04-d158-4bfb-8750-bfb724605cdd","acronym":"P30CA016672","url":"https://clinicaltrials.gov/study/NCT03383575","created_at":"2021-01-18T16:41:48.451Z","updated_at":"2025-02-25T14:37:54.258Z","phase":"Phase 2","brief_title":"Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome","source_id_and_acronym":"NCT03383575 - P30CA016672","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • IDH2 • RUNX1 • ASXL1","pipe":" | ","alterations":" IDH2 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation","tags":["TP53 • IDH2 • RUNX1 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 01/17/2018","start_date":" 01/17/2018","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-10"},{"id":"e3936c5c-e8c6-4488-bd75-cc3cc84c9df4","acronym":"NCI-2018-01789","url":"https://clinicaltrials.gov/study/NCT03661307","created_at":"2021-01-18T17:57:55.790Z","updated_at":"2025-02-25T15:25:53.725Z","phase":"Phase 1/2","brief_title":"Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT03661307 - NCI-2018-01789","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • FLT3 mutation • TP53 deletion","tags":["TP53 • FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • FLT3 mutation • TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Vanflyta (quizartinib) • decitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 10/31/2018","start_date":" 10/31/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-10"},{"id":"74bef0ec-e64e-4efc-a1bb-a54c18f7a818","acronym":"","url":"https://clinicaltrials.gov/study/NCT04220684","created_at":"2021-01-18T20:32:37.858Z","updated_at":"2025-02-25T16:32:03.029Z","phase":"Phase 1","brief_title":"Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML","source_id_and_acronym":"NCT04220684","lead_sponsor":"Sumithira Vasu","biomarkers":" IL21","pipe":"","alterations":" ","tags":["IL21"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • decitabine • fludarabine IV • SAR445419"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 06/11/2020","start_date":" 06/11/2020","primary_txt":" Primary completion: 10/22/2024","primary_completion_date":" 10/22/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-07"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"84b9efcf-36bd-4449-8f61-5a867dd8b5f1","acronym":"NCI-2020-04163","url":"https://clinicaltrials.gov/study/NCT04435691","created_at":"2021-01-18T21:21:23.231Z","updated_at":"2025-02-25T16:37:56.003Z","phase":"Phase 1/2","brief_title":"Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia","source_id_and_acronym":"NCT04435691 - NCI-2020-04163","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 deletion","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • magrolimab (ONO-7913)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 07/28/2020","start_date":" 07/28/2020","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-06"},{"id":"cfc49a74-4ea2-4c0c-b519-268b184b6efd","acronym":"SWOG-S0703","url":"https://clinicaltrials.gov/study/NCT00658814","created_at":"2021-01-29T06:58:25.253Z","updated_at":"2025-02-25T16:43:30.772Z","phase":"Phase 2","brief_title":"Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia","source_id_and_acronym":"NCT00658814 - SWOG-S0703","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 06/01/2013","primary_completion_date":" 06/01/2013","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-06"},{"id":"268eae36-cdca-45ae-8506-36b3e8cbd7f6","acronym":"BLAST MRD AML-2","url":"https://clinicaltrials.gov/study/NCT04284787","created_at":"2024-03-22T03:46:14.077Z","updated_at":"2025-02-25T17:00:27.213Z","phase":"Phase 2","brief_title":"BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT04284787 - BLAST MRD AML-2","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD8 • PD-1 • IFNG • GZMB • FOXP3","pipe":" | ","alterations":" PD-L1 expression • Chr t(15;17)","tags":["PD-L1 • CD8 • PD-1 • IFNG • GZMB • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Venclexta (venetoclax) • azacitidine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/16/2021","start_date":" 02/16/2021","primary_txt":" Primary completion: 06/05/2023","primary_completion_date":" 06/05/2023","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-03"},{"id":"be0a0acb-715b-4bf3-8af3-8a6314e2a31f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06514261","created_at":"2025-02-25T20:15:15.595Z","updated_at":"2025-02-25T20:15:15.595Z","phase":"Phase 1","brief_title":"Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML","source_id_and_acronym":"NCT06514261","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • BCL2 • NF1 • MCL1 • BCL2L1 • BAX","pipe":"","alterations":" ","tags":["TP53 • BCL2 • NF1 • MCL1 • BCL2L1 • BAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • iadademstat (ORY-1001)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 12/18/2024","start_date":" 12/18/2024","primary_txt":" Primary completion: 09/16/2026","primary_completion_date":" 09/16/2026","study_txt":" Completion: 09/16/2026","study_completion_date":" 09/16/2026","last_update_posted":"2025-01-16"},{"id":"fec24dde-5495-487a-9638-f611fd8adb35","acronym":"","url":"https://clinicaltrials.gov/study/NCT06763341","created_at":"2025-02-26T07:13:37.175Z","updated_at":"2025-02-26T07:13:37.175Z","phase":"Phase 1","brief_title":"AOH1996 Alone or in Combination With Venetoclax With or Without Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT06763341","lead_sponsor":"City of Hope Medical Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/16/2025","start_date":" 08/16/2025","primary_txt":" Primary completion: 01/16/2027","primary_completion_date":" 01/16/2027","study_txt":" Completion: 01/16/2027","study_completion_date":" 01/16/2027","last_update_posted":"2025-01-08"},{"id":"84edb0cb-23b4-41c9-a4af-3815707a7019","acronym":"","url":"https://clinicaltrials.gov/study/NCT05958719","created_at":"2025-02-26T07:45:46.896Z","updated_at":"2025-02-26T07:45:46.896Z","phase":"Phase 2","brief_title":"Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma","source_id_and_acronym":"NCT05958719","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" IFNG • IL6 • TNFA • IL10 • IFNA1","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • prednisone • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 03/02/2023","start_date":" 03/02/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 03/02/2027","study_completion_date":" 03/02/2027","last_update_posted":"2024-12-30"}]